Results 41 to 50 of about 125,343 (247)

Predictors of Non-Variceal Hemorrhage in a National Cohort of Patients With Chronic Liver Disease. [PDF]

open access: yesJ Hematol
BACKGROUND: Non-variceal hemorrhage in patients with chronic liver disease (CLD) increases morbidity, mortality, and healthcare costs. There are limited data on risk factors for non-variceal hemorrhage in the CLD population.
Afzal A   +6 more
europepmc   +2 more sources

Motion – Prophylactic Banding of Esophageal Varices Is Useful: Arguments for the Motion

open access: yesCanadian Journal of Gastroenterology, 2002
Variceal hemorrhage is a frequent complication of cirrhosis and is associated with a high mortality rate, especially in patients with decompensated liver disease.
Gregory V Stiegmann
doaj   +1 more source

Pathophysiology and Treatment of Variceal Hemorrhage [PDF]

open access: yesMayo Clinic Proceedings, 1996
Portal hypertension results from increases in portal flow and portal vascular resistance. Factors increasing portal blood flow are predominantly humoral. Resistance to portal flow has a fixed component due to distortion of the vasculature by cirrhotic nodules and a variable component that is related to vasoactive substances.
L R, Roberts, P S, Kamath
openaire   +2 more sources

Improved Survival with the Patients with Variceal Bleed [PDF]

open access: yes, 2011
Variceal hemorrhage is a major cause of death in patients with cirrhosis. Over the past two decades new treatment modalities have been introduced in the management of acute variceal bleeding (AVB) and several recent studies have suggested that the ...
Shiv K. Sarin, Praveen Sharma
core   +1 more source

Endoscopic Approaches to the Treatment of Variceal Hemorrhage in Hemodialysis-Dependent Patients

open access: yesGastroenterology Research and Practice, 2016
Background. Esophagogastric variceal hemorrhage leads to challenging situation in chronic kidney disease patients on maintenance hemodialysis. Aims. To determine the safety and efficacy of endoscopic approaches to patients with hemodialysis-dependent ...
Xiaoquan Huang   +5 more
doaj   +1 more source

C-clamp and pelvic packing for control of hemorrhage in patients with pelvic ring disruption [PDF]

open access: yes, 2011
BACKGROUND: Exsanguinating hemorrhage is the major cause of death in patients with pelvic ring disruption. AIMS: The aim of this study was to document outcomes after the stabilization of pelvic ring injuries by a C-clamp and control of hemorrhage ...
Meier, C   +12 more
core   +1 more source

Transjugular intrahepatic portosystemic shunt for the management of acute variceal hemorrhage.

open access: yes, 2013
International audienceAcute variceal hemorrhage, a life-threatening condition that requires a multidisciplinary approach for effective therapy, is defined as visible bleeding from an esophageal or gastric varix at the time of endoscopy, the presence of ...
Loffroy, Romaric   +11 more
core   +1 more source

Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club [PDF]

open access: yes, 2005
Sepsis is a systemic inflammatory response to the presence of infection, mediated via the production of many cytokines, including tumour necrosis factor alpha (TNF-alpha), interleukin (IL)-6, and IL-1, which cause changes in the circulation ...
Wong, F.   +23 more
core   +1 more source

Genotype–Phenotype Correlations of Monoallelic PFIC Variants in Pediatric Liver Disease: A Multicenter Retrospective Cohort Study

open access: yesAmerican Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Progressive familial intrahepatic cholestasis (PFIC) is classically caused by biallelic pathogenic variants, yet monoallelic variants of uncertain significance (VUS) in PFIC‐associated genes are increasingly identified in children with cholestasis, creating diagnostic uncertainty.
Brett J. Hoskins   +9 more
wiley   +1 more source

Intravenous tPA therapy does not worsen acute intracerebral hemorrhage in mice [PDF]

open access: yes, 2013
Tissue plasminogen activator (tPA) is the only FDA-approved treatment for reperfusing ischemic strokes. But widespread use of tPA is still limited by fears of inadvertently administering tPA in patients with intracerebral hemorrhage (ICH).
Emiri Mandeville   +58 more
core   +2 more sources

Home - About - Disclaimer - Privacy